Share

Canagliflozin Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

Canagliflozin improves renal outcomes in people with type 2 diabetes mellitus (T2DM) with or at high risk for cardiovascular (CV) disease, according to data recently presented at the 2018 National Kidney Foundation’s Spring Clinical Meetings in Austin, Texas.. This benefit was observed in people with both preserved and reduced kidney function, as measured by estimated...